# A Study of MRX2843 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

> **NCT04946890** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Betta Pharmaceuticals Co., Ltd.** · enrollment: 104 (estimated)

## Conditions studied

- Acute Myeloid Leukemia Leukemia

## Interventions

- **DRUG:** MRX2843

## Key facts

- **NCT ID:** NCT04946890
- **Lead sponsor:** Betta Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07-01
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 104 (ESTIMATED)
- **Last updated:** 2021-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04946890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04946890, "A Study of MRX2843 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04946890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*